annual
individu
receiv
hematopoiet
stem
cell
transplant
sct
worldwid
sct
recipi
higher
risk
sever
infect
sinc
often
remain
state
immunosuppress
transplant
depend
comorbid
graftversushost
diseas
gvhd
need
immunosuppress
drug
particular
sct
recipi
suscept
common
respiratori
virus
crv
owe
impair
tcell
crv
common
caus
upper
respiratori
tract
diseas
urd
lower
respiratori
tract
diseas
lrd
popul
associ
signific
morbid
date
preliminari
studi
infect
caus
crv
among
sct
recipi
howev
epidemiolog
individu
crv
vari
accord
region
time
mani
advanc
diagnosi
treatment
infect
caus
crv
achiev
present
studi
aim
describ
incid
clinic
cours
risk
factor
mortal
associ
lrd
caus
crv
sct
recipi
singl
sct
center
korea
retrospect
review
medic
record
patient
age
year
undergon
sct
januari
august
cathol
blood
marrow
transplant
centr
seoul
st
mari
hospit
cathol
univers
korea
seoul
republ
korea
aim
identifi
lrd
caus
crv
crv
associ
lrd
patient
includ
influenza
b
virus
respiratori
syncyti
viru
rsv
human
parainfluenza
viru
hpiv
human
rhinoviru
hrhv
human
adenoviru
hadv
human
metapneumoviru
hmpv
clinic
inform
includ
demograph
comorbid
coinfect
mortal
investig
endpoint
studi
set
januari
time
death
loss
follow
studi
approv
institut
review
board
yeouido
seoul
st
mari
hospit
approv
no
sct
recipi
respiratori
symptom
screen
crv
discret
physician
specimen
diagnost
test
includ
nasal
throat
swab
sputum
tracheal
aspir
bronchial
wash
fluid
bronchoalveolar
lavag
bal
fluid
laboratori
test
identifi
crv
includ
respiratori
viru
polymeras
chain
reaction
pcr
multiplex
panel
advansur
rv
realtim
pcr
kit
lg
life
scienc
seoul
korea
rapid
influenza
antigen
test
bd
veritor
system
rapid
detect
flu
ab
bd
diagnost
spark
md
usa
respiratori
viru
pcr
multiplex
panel
use
test
influenza
b
virus
rsv
hmpv
hpiv
hrhv
hadv
influenzaspecif
revers
transcript
pcr
use
detect
influenza
pandem
urd
defin
detect
crv
upper
respiratori
secret
nasal
throat
swab
associ
respiratori
symptom
includ
cough
rhinorrhea
sore
throat
absenc
new
infiltr
chest
lrd
defin
acut
respiratori
ill
dyspnea
hypoxia
pulmonari
infiltr
occur
associ
detect
crv
respiratori
assess
radiograph
find
includ
chest
radiographi
comput
tomographi
scan
base
formal
read
radiolog
specialist
hospitalacquir
infect
defin
symptom
onset
day
hospit
presenc
copathogen
defin
isol
pathogen
bacteri
speci
fungal
speci
opportunist
virus
cytomegaloviru
cmv
respiratori
specimen
obtain
within
month
detect
crv
conjunct
consist
symptom
confirm
infecti
diseas
proven
probabl
invas
fungal
diseas
defin
accord
criteria
european
organ
research
treatment
cancerinvas
fungal
infect
cooper
group
nation
institut
allergi
infecti
diseas
mycos
studi
group
consensu
group
mix
crv
infect
defin
isol
two
crv
episod
mortal
due
lrd
caus
crv
defin
death
result
respiratori
failur
period
complet
recoveri
onset
ill
death
within
day
without
document
overal
mortal
defin
death
caus
within
day
follow
diagnosi
crvlrd
absolut
lymphocyt
count
alc
blood
within
week
preced
crv
infect
diagnosi
defin
lymphopenia
absolut
neutrophil
count
anc
blood
within
week
prior
crv
infect
defin
dosag
corticosteroid
use
classifi
three
group
accord
highest
daili
dose
taken
patient
week
preced
crv
infect
highdos
corticosteroid
use
defin
mgkgday
prednison
equival
dose
corticosteroid
lowdos
use
defin
mgkgday
prednison
third
group
receiv
topic
grade
immunodefici
classifi
three
group
includ
sever
moder
mild
sever
immunodefici
sid
defin
presenc
two
follow
allogen
sct
allosct
within
month
autolog
sct
autosct
within
month
preced
diagnosi
crv
infect
acut
gvhd
grade
alc
anc
within
week
diagnosi
preengraft
period
administr
immunosuppress
therapi
week
prior
diagnosi
moder
immunodefici
mid
defin
presenc
one
criteria
sid
two
follow
criteria
allosct
within
year
month
autosct
within
month
month
prior
diagnosi
crv
infect
alc
anc
within
week
diagnosi
administr
immunosuppress
drug
within
month
prior
diagnosi
patient
met
one
criterion
mid
regard
mild
immunodefici
state
analys
perform
first
episod
crv
infect
sct
categor
variabl
describ
number
percentag
continu
variabl
express
median
interquartil
rang
deviat
categor
variabl
compar
use
chisquar
fisher
exact
test
continu
variabl
compar
use
ttest
wilcoxon
ranksum
test
use
cox
proport
hazard
regress
model
variabl
p
upon
univari
analysi
includ
multivari
logist
regress
analysi
determin
signific
risk
factor
mortal
associ
crvlrd
p
valu
twotail
statist
signific
set
p
statist
analys
perform
use
sa
version
sa
institut
inc
cari
nc
usa
total
patient
receiv
sct
autolog
allogen
januari
august
period
crvlrd
identifi
patient
coinfect
two
crv
observ
patient
influenza
viru
rsv
coinfect
observ
two
patient
hpiv
hrhv
coinfect
observ
one
patient
hpiv
rsv
coinfect
also
observ
one
patient
baselin
characterist
sct
recipi
crvlrd
shown
tabl
winter
rsv
influenza
viru
predomin
crv
proport
hpiv
infect
increas
spring
summer
fig
analysi
cumul
incid
first
crvlrd
episod
demonstr
common
caus
pathogen
crvlrd
day
cumul
incid
estim
confid
interv
ci
year
sct
cumul
incid
estim
ci
hpiv
cumul
incid
estim
rsv
ci
two
patient
present
lrd
caus
influenza
viru
hrhv
one
patient
day
follow
sct
fig
cumul
incid
estim
lrd
caus
influenza
viru
rsv
hpiv
hrhv
year
sct
ci
ci
ci
ci
respect
fig
characterist
lrd
caus
variou
crv
describ
tabl
common
type
extent
radiograph
infiltr
influenzacaus
lrd
alveolar
pattern
bilater
lung
field
respect
seven
patient
influenzalrd
receiv
antivir
therapi
receiv
within
hour
follow
influenzalrd
diagnosi
howev
earli
antivir
therapi
within
hour
symptom
onset
perform
patient
one
patient
receiv
combin
therapi
peramivir
mgday
day
oseltamivir
mgday
day
five
patient
experienc
mechan
ventil
overal
mortal
rate
patient
two
patient
diagnos
influenza
viru
one
die
due
respiratori
failur
day
follow
diagnosi
patient
rsvlrd
hospitalacquir
receiv
antivir
therapi
overal
mortal
rate
patient
two
patient
rsvlrd
treat
oral
ribavirin
one
aerosol
ribavirin
receiv
intraven
immunoglobulin
ivig
gkg
day
patient
receiv
aerosol
ribavirin
ivig
surviv
wherea
two
patient
treat
oral
ribavirin
die
seven
patient
hpivlrd
receiv
oral
ribavirin
mgday
day
overal
mortal
rate
patient
hpivlrd
four
seven
patient
hrhvlrd
requir
mechan
ventil
mortal
rate
patient
copathogen
isol
respiratori
specimen
detect
patient
crvlrd
common
bacteri
copathogen
acinetobact
baumannii
follow
pseudomona
aeruginosa
streptococcu
pneumonia
aspergillu
speci
detect
patient
cmvpcr
bal
fluid
posit
two
patient
patient
die
without
pneumonia
caus
death
one
due
septic
shock
result
infecti
coliti
one
due
diffus
alveolar
hemorrhag
overal
mortal
day
diagnosi
crvlrd
univari
analysi
highdos
steroid
usag
sid
lymphopenia
significantli
associ
mortal
within
day
follow
crvlrd
diagnosi
tabl
multivari
logist
regress
analysi
reveal
use
highdos
steroid
odd
ratio
ci
lymphopenia
ci
independ
risk
factor
mortal
within
day
crvlrd
detect
tabl
almost
data
respiratori
viru
infect
among
sct
recipi
korea
studi
aim
retrospect
collect
analyz
data
regard
epidemiolog
risk
factor
lrd
caus
crv
sct
recipi
largest
sct
center
korea
incid
influenzaassoci
lrd
among
sct
recipi
report
studi
rang
mortal
rate
previou
studi
proport
progress
pneumonia
among
influenza
virusinfect
sct
recipi
report
mortal
rate
influenzalrd
center
consist
previou
report
rsv
infect
report
occur
adult
sct
incid
mortal
rate
rsvlrd
among
sct
recipi
report
find
consist
incid
mortal
rate
rsvlrd
observ
center
spite
low
rate
ribavirin
treatment
known
risk
factor
rsvassoci
mortal
sct
patient
includ
preengraft
lymphopenia
allosct
month
previous
sid
older
age
year
highest
incid
rsv
occur
januari
april
consist
result
major
rsvlrd
detect
decemb
symptomat
hpiv
infect
report
occur
adult
sct
recipi
previou
report
frequenc
mortal
rate
hpivlrd
among
sct
recipi
mortal
rate
hpivlrd
center
similar
previou
studi
despit
low
rate
antivir
treatment
sinc
hpiv
show
highest
cumul
incid
lrd
day
ci
year
ci
follow
sct
perform
laboratori
examin
import
due
nonspecif
respiratori
symptom
independ
predictor
hpivassoci
death
report
literatur
includ
steroid
usag
cancer
statu
acut
physiolog
chronic
health
evalu
ii
score
lrd
infect
immedi
follow
sct
day
mismatch
donor
need
mechan
ventil
presenc
similarli
highdos
steroid
usag
time
diagnosi
one
independ
predictor
death
among
sct
recipi
crvlrd
present
studi
furthermor
present
studi
demonstr
hpiv
infect
preval
summer
month
follow
spring
report
previou
studi
report
incid
hrhvlrd
among
sct
recipi
rare
hrhvlrd
associ
low
mortal
present
studi
incid
hrhvlrd
patient
associ
mortal
rate
patient
result
consist
preced
studi
hrhv
may
caus
sever
infect
sct
recipi
high
rate
progress
lrd
ison
et
report
sct
recipi
pneumonia
hrhv
detect
bal
signific
coinfect
suggest
hrhv
might
caus
frequent
superinfect
possibl
lytic
infect
indirect
immunosuppress
effect
studi
also
indic
patient
hrhvlrd
posit
presenc
copathogen
hadv
shown
infect
sct
recipi
subsequ
mortal
rate
high
hmpvlrd
report
occur
sct
recipi
progress
howev
case
hadvlrd
hmpvlrd
observ
patient
cohort
crv
infect
may
contribut
sustain
inflamm
activ
inflammatori
process
lead
irrevers
airway
damag
caus
late
airflow
obstruct
sct
furthermor
crv
infect
frequent
coexist
bacteri
fungal
pathogen
contribut
develop
pneumonia
may
result
epitheli
damag
impair
ciliari
function
alter
immun
respons
upregul
bacteri
receptor
crvinfect
respiratori
addit
sever
report
sct
recipi
shown
lower
immun
respons
influenza
vaccin
compar
observ
gener
sever
immunocompromis
patient
sct
recipi
report
show
prolong
influenza
shed
result
develop
antivir
resist
prolong
antivir
therapi
present
studi
highdos
steroid
usag
lymphopenia
shown
risk
factor
mortal
sct
recipi
crvlrd
lymphopenia
previous
report
risk
factor
mortal
among
sct
patient
lrd
caus
influenza
addit
highdos
steroid
usag
week
preced
crvlrd
diagnosi
report
independ
predictor
mortal
among
sct
recipi
like
two
risk
factor
associ
decreas
tcellmedi
immun
furthermor
highdos
corticosteroid
use
known
associ
trend
toward
delay
viral
convers
previou
studi
report
use
corticosteroid
exert
protect
effect
progress
pneumonia
requir
mechan
ventil
among
sct
recipi
influenzalrd
hypothes
occur
due
salutari
immunomodulatori
sever
limit
present
studi
retrospect
studi
standard
guidelin
screen
treatment
crv
infect
howev
overcom
limit
crvlrd
case
includ
due
small
number
case
possibl
analyz
risk
factor
mortal
individu
crvlrd
anoth
limit
difficult
determin
whether
fatal
outcom
sole
attribut
crv
due
combin
crv
copathogen
howev
precis
discrimin
pathogen
would
like
meaningless
sinc
damag
respiratori
epithelium
result
crv
infect
may
key
factor
facilit
occurr
recent
studi
show
viral
nucleic
acid
detect
bloodstream
frequent
among
sct
recipi
lrd
caus
influenza
rsv
hadv
hmpv
associ
increas
mortal
therefor
viral
nucleic
acid
detect
bloodstream
sct
recipi
crvlrd
could
use
predict
diseas
sever
poor
outcom
need
intensifi
antivir
treatment
futur
studi
demonstr
crvlrd
signific
morbid
mortal
among
sct
recipi
thu
implement
activ
diagnost
approach
crv
infect
requir
sct
recipi
respiratori
symptom
sct
recipi
lrd
caus
influenza
rsv
hpiv
infect
receiv
highdos
steroid
treatment
lymphopenia
earli
antivir
treatment
consid
especi
consid
fact
vaccin
yet
avail
rsv
hpiv
furthermor
infect
control
measur
includ
hand
hygien
respiratori
droplet
isol
reduc
occurr
new
infect
transmiss
import
crv
without
specif
antivir
treatment
option
hrhv
hmpv
final
order
prevent
lrd
caus
influenza
crv
avail
vaccin
annual
season
influenza
vaccin
recommend
sct
recipi
